Takeda estimates £162.50 million hit to operating loss as Novartis withdraws from European approval for XiidraInvezz • 06/29/20
Japan's Takeda expects $200 million operating loss related to Novartis' Xiidra withdrawalReuters • 06/29/20
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Novartis AG – NVSBusiness Wire • 06/26/20
UPDATE: Swiss drug company Novartis settles with DoJ, SEC in case brought under Foreign Corrupt Practices ActMarket Watch • 06/25/20
Swiss drug company Novartis settles with DoJ, SEC in case brought under Foreign Corrupt Practices ActMarket Watch • 06/25/20
FDA Revokes Emergency Use Authorization for Hydroxychloroquine and Chloroquine as COVID-19 TreatmentsThe Motley Fool • 06/15/20
Big Day for Data: GDP, Jobless Claims, Novartis, Durable Goods & MoreZacks Investment Research • 05/28/20